Tvardi Therapeutics, Inc.
TVRD
$1.89
-$0.05-2.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.63M | 2.14M | 2.10M | 2.34M | 3.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.63M | 7.05M | 7.59M | 5.94M | 8.87M |
| Operating Income | -6.63M | -7.05M | -7.59M | -5.94M | -8.87M |
| Income Before Tax | -6.46M | -6.80M | -7.28M | -5.53M | 4.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.46M | -6.80M | -7.28M | -5.53M | 4.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.46M | -6.80M | -7.28M | -5.53M | 4.17M |
| EBIT | -6.63M | -7.05M | -7.59M | -5.94M | -8.87M |
| EBITDA | -6.61M | -7.03M | -7.56M | -5.91M | -8.85M |
| EPS Basic | -0.69 | -0.73 | -0.78 | -0.59 | 0.51 |
| Normalized Basic EPS | -0.43 | -0.45 | -0.48 | -0.37 | 0.32 |
| EPS Diluted | -0.69 | -0.73 | -0.78 | -0.59 | -1.00 |
| Normalized Diluted EPS | -0.43 | -0.45 | -0.48 | -0.37 | 0.31 |
| Average Basic Shares Outstanding | 9.38M | 9.38M | 9.38M | 9.38M | 8.25M |
| Average Diluted Shares Outstanding | 9.38M | 9.38M | 9.38M | 9.38M | 8.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |